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Abstract: The role of Aspergillus fumigatus in the airways of chronic obstructive pulmonary disease
(COPD) patients with bronchiectasis is currently unclear. We searched for a sensitive and noninvasive
method for A. fumigatus detection in the sputum of COPD patients and addressed potential risk
factors for its presence. Induced sputum samples of 18 COPD patients and 17 COPD patients
with bronchiectasis were analyzed for the presence of A. fumigatus by culture, galactomannan
detection, and PCR. Of the patients with COPD–bronchiectasis overlap, 23.5% had a positive culture
for A. fumigatus versus 10.5% of COPD patients without bronchiectasis (p = 0.39). The median
sputum galactomannan optical density index was significantly higher in patients with COPD and
bronchiectasis compared with patients with COPD alone (p = 0.026) and ranged between the levels of
healthy controls and A. fumigatus-colonized cystic fibrosis patients. Both the presence of bronchiectasis
and the administration of systemic corticosteroids were associated with sputum galactomannan
(p = 0.0028 and p = 0.0044, respectively) and showed significant interaction (p interaction = 0.022).
PCR for Aspergillus was found to be a less sensitive method, but was critically dependent on the
extraction technique. The higher sputum galactomannan levels suggest a more abundant presence of
A. fumigatus in the airways of patients with COPD–bronchiectasis overlap compared with patients
with COPD without bronchiectasis, particularly when systemic corticosteroids are administered.
Keywords: sputum galactomannan; Aspergillus PCR; Aspergillus colonization; corticosteroids
1. Introduction
Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease, characterized by
progressive airflow limitation, which is caused by an abnormal inflammatory response to chronic
inhalation of irritants, mainly cigarette smoke [1]. Both small airways (obstructive bronchiolitis)
and parenchyma (emphysema) are affected. Bronchiectasis is defined by the presence of irreversibly
dilated and chronically inflamed bronchi. COPD and bronchiectasis have overlapping clinical features,
but the diagnostic criteria are very different. Whereas an irreversible obstructive lung function is
obligatory in COPD, bronchiectasis is diagnosed by structural airway abnormalities observed on
computed tomography (CT) of the thorax. The combined presence of COPD and bronchiectasis in
one patient is not rare. In cohorts of COPD patients, bronchiectasis has been described in 30–60% of
patients [2–5], whereas bronchiectasis cohorts report COPD as the underlying cause in approximately
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30% of patients [6,7].The recognition of an overlap is relevant, since these patients not only have a
worse prognosis [2,7,8], but their diagnostic and therapeutic approach is also different.
The pathogenesis of bronchiectasis is generally explained by a vicious circle of inflammation,
structural damage, impaired mucus clearance, bacterial colonization, and infection [9]. The underlying
mechanism for the development of bronchiectasis in a subset of COPD patients remains largely
unknown. Aspergillus fumigatus is a ubiquitous fungus, which is cleared from the airways by the
innate immune system. A damaged airway epithelium, inherited or acquired defects of the innate
immune system, and immunosuppressive drugs such as corticosteroids (CS) predispose to aspergillosis.
A. fumigatus colonization and sensitization associate with bronchiectasis and unfavorable outcomes
in asthma and cystic fibrosis (CF) [10–13]. In COPD, a history of exacerbations and the isolation of
pathogenic bacteria in sputum were suggested as potential risk factors for A. fumigatus [14]. Although
the clinical relevance is not clear, several retrospective studies showed that more than 20% of COPD
patients with A. fumigatus detected in respiratory samples eventually developed aspergillosis [15,16].
If A. fumigatus plays a causal role in the development of bronchiectasis is still a matter of debate.
One major reason for our limited understanding is the lack of sensitive and noninvasive methods
to detect A. fumigatus in the airways. Mycological culture is not sensitive nor standardized and has led
to an underestimation of A. fumigatus in the airways [17]. Other methods focus mainly on invasive
fungal disease and require invasive procedures, such as immunohistochemistry on airway biopsies or
galactomannan detection on bronchoalveolar lavage fluid. Galactomannan is a polysaccharide cell wall
component of Aspergillus species, which is not present in resting conidia but is secreted by the hyphae
during fungal growth. The determination of galactomannan by enzyme immunoassay in serum and
bronchoalveolar lavage fluid is validated for diagnosing an invasive Aspergillus disease, mainly in
immunocompromised patients. Molecular-based techniques such as polymerase chain reaction (PCR)
and next-generation sequencing are hampered by complex DNA extraction, high costs, and limited
experience with sputum samples. To investigate the role of A. fumigatus in patients with COPD,
we explored the feasibility of galactomannan detection and A. fumigatus PCR on sputum samples.
We assumed a more abundant presence of A. fumigatus in the sputum of patients with
COPD-bronchiectasis overlap and addressed the role of CS as a potential risk factor.
2. Results
2.1. Study Group Characteristics
Thirty-six COPD patients were included, of which 17 had bronchiectasis, with a median modified
Reiff score of 4. There were no significant differences between the two groups, apart from a significantly
lower median value of pack-years (p = 0.048) in patients with bronchiectasis. The results are shown
in Table 1.
Table 1. Characteristics of the study groups.
characteristic COPD without Bronchiectasis COPD with Bronchiectasis
Subjects, n 19 17
Hospitalized, % 42 65
Age, y 71 (60–75) 68 (63–79)
Male, % 84 88
BMI, kg/m2 25 (20–30) 22 (19–27)
Pack-years * 48 (40–55) 40 (25–45)
FEV1, % pred 51 (39–58) 41 (37–52)
DLCO, % pred 47 (40–57) 44 (26–53)
GOLD
I/II/III/IV, % 0/53/47/0 6/29/65/0
A/B/C/D, % 21/0/16/63 12/17/6/65
Eosinophils, % 1.4 (0.1–3.1) 2.3 (0.8–4.6)
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Table 1. Cont.
Characteritic COPD without Bronchiectasis COPD with Bronchiectasis
Eosinophils, µL 200 (0–300) 200 (100–350)
Total IgE, kU/L 83 (16–592) 43 (33–298)
mMRC 2 (1–2) 2 (1.5–3.5)
CAT 14 (12–20) 19 (13–24)
SGRQ 41.9 (30.6–53.4) 54.9 (37.3–66.7)
≥2 exacerbations/y, % 79 71
ICS, % 89 82
Modified Reiff score NA 4 (2.5–6.5)
Data are presented as n, % or median (interquartile range). COPD: chronic obstructive pulmonary disease, y: year,
BMI: body mass index, FEV1: forced expiratory volume in 1 s, % pred: percentage predicted, DLCO: diffusion
capacity of the lung for carbon monoxide, GOLD: Global initiative for chronic Obstructive Lung Disease stadia,
mMRC: modified Medical Research Council breathlessness scale, CAT: COPD Assessment Test, SGRQ: Saint Georges
Respiratory Questionnaire, ICS: inhaled corticosteroids. * p-value < 0.05. All other variables were not significantly
different between the groups.
2.2. A. fumigatus Antibodies
Patients with COPD-bronchiectasis overlap had a median A. fumigatus IgG value of 35.4 mg/L
versus 17.4 mg/L in COPD patients without bronchiectasis (p = 0.14). On the basis of both ImmunoCAP
measurement and skin prick test, three patients without (15.7%) and five patients with bronchiectasis
(29.4%) were sensitized to A. fumigatus (p = 0.37). The results are summarized in Table 2.
Table 2. A. fumigatus-related results.
Test COPD without Bronchiectasis COPD with Bronchiectasis p-Value
Subjects, n 19 17
A. fumigatus IgG, mg/L 17.4 (13.4–37.3) 35.4 (25.5–51.6) 0.14
A. fumigatus sensitization, % 15.7 29.4 0.37
A. fumigatus sputum culture, % 10.5 23.5 0.39
Sputum galactomannan, ODI 0.7 (0.4–1.5) 3.7 (0.6–5.7) 0.026
Data are presented as n, median (interquartile range) or %. COPD: chronic obstructive pulmonary disease,
A. fumigatus: Aspergillus fumigatus, ODI: optical density index. p-Value < 0.05 is captured in bold.
2.3. Fungal Sputum Culture
Four COPD patients with bronchiectasis (23.5%) had a positive A. fumigatus culture versus
two COPD patients without bronchiectasis (10.5%) (p = 0.39). Aspergillus nidulans was found in
samples of two COPD–bronchiectasis-overlap patients which were also positive for A. fumigatus.
When only inocula of 10 µL were considered, three out of six positive cultures were negative. Of the
non-inoculated control plates and of the healthy control samples, none grew A. fumigatus, but a positive
A. fumigatus culture was confirmed in all samples of cystic fibrosis patients with previously known
A. fumigatus colonization.
2.4. Sputum Galactomannan
The median sputum galactomannan ODI was significantly higher in patients with COPD-
bronchiectasis overlap compared with patients with only COPD (3.7 versus 0.7, p = 0.026) (Table 2).
The results of galactomannan measurements in Sputasol, sterile water, and three vials of amoxicillin
clavulanate were 0.0, 0.1, and 0.0 respectively. Thirteen sputum samples were retested and had a
median galactomannan inter-assay difference of 0.4, with a median coefficient of variation of 9.4%
(Supplementary Materials Table S1). The majority of patients was using inhalation corticosteroids
(ICS) (Table 1); we found no difference in sputum galactomannan between patients without ICS or
with medium or high dose ICS (Figure 1). In contrast to ICS, both bronchiectasis and systemic CS
were significantly associated with sputum galactomannan ODI (p = 0.0028 and p = 0.0044 respectively)
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in a two-way analysis of variance model. Furthermore, CS showed a stronger association with
galactomannan in the patients with COPD–bronchiectasis overlap compared with COPD patients
without bronchiectasis (p interaction = 0.022). The results are presented in Figure 2 and Table 3.
As galactomannan detection on sputum has not been validated, we compared our results to negative
and positive control samples and found them to be significantly different (p = 0.0012, Figure 3).
Moreover, all but one subjects with a positive A. fumigatus culture had a sputum galactomannan ODI
above 4 (Supplementary Materials Table S2).
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Figure 2. Effect of systemic corticosteroids on sputum galactomannan values. Sputum galactomannan 
is presented as optical density index. Every dot represents one sample, and the horizontal lines reflect 
the median values. ODI: optical density index, COPD: chronic obstructive pulmonary disease, CS: 
systemic corticosteroids in the previous seven days. 
Table 3. Associations with sputum galactomannan in COPD patients. 
Bivariate Models
Estimate p-Value 
CS in COPD without bronchiectasis (n = 19) 0.64 0.54 
CS in COPD with bronchiectasis (n = 17) 4.17 0.0004 
Multivariate Model
Estimate p-Value 
Bronchiectasis 0.67 0.0028 
CS 0.57 0.0044 
Antibiotics 0.37 0.63 
Bronchiectasis–CS interaction 3.43 0.022 
Two bivariate general linear models were built with galactomannan as exposure: one for patients 
without and one for patients with bronchiectasis showing that CS were only significant associated with 
galactomannan in patients having bronchiectasis. One multivariate (two-way analysis of variance) 
general linear model was built for all patients in which systemic corticosteroids and antibiotics 
administered in the seven days before sputum induction were considered relevant. CS: systemic 
corticosteroids, COPD: chronic obstructive pulmonary disease, p-values < 0.05 are shown in bold. 
Figure 1. Inhaled corticosteroids and sputum galactomannan. Sputum galactomannan is presented as
optical density index. Every dot represents one sample, and the horizontal lines reflect the median values.
There was no significant difference in galactomannan values dependent on ICS dose. ODI: optical density
index, ICS: inhaled corticosteroids.
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Figure 2. Effect of systemic corticosteroids on sputum galactomannan values. Sputum galactomannan
is presented as optical density index. Every dot represents one sample, and the horizontal lines
reflect the median values. ODI: optical density index, COPD: chronic obstructive pulmonary disease,
CS: systemic corticosteroids in the previous seven days.
Table 3. Associations with sputum galactomannan in COPD patients.
Bivariate Models
Estimate p-Value
CS in COPD without bronchiectasis (n = 19) 0.64 0.54
CS in COPD with bronchiectasis (n = 17) 4.17 .0004
Multivariate Model
Estimate p-Value
Bronchiectasis 0.67 0.0028
CS 0.57 0.0044
Antibiotics 0.37 0.63
Bronchiectasis–CS interaction 3.43 0.022
Two bivariate general linear models were built with galactomannan as exposure: one for patients without and
one for patients with bronchiectasis showing that CS were only significant associated with galactomannan in
patients hav ng bronchiectasis. One multivariate ( wo-way analysis of varianc ) gen ral linear model was built
for all patients in which systemic corticosteroids and antibiotics administered in the seven days before sputum
induction were considered relevant. CS: systemic corticosteroids, COPD: chronic obstructive pulmonary disease,
p-values < 0.05 are shown in bold.
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Figure 3. Comparison of COPD sput m gal ctoman it healthy and A. fumigatus-colonized CF
controls. Sputum galactomannan is presented as optical density index. Every dot represents one sample,
and the horizontal lines reflect the median values. Kruskal–Wallis test showed an overall significant
difference (p = 0.0012), with Dunn’s post-hoc comparison for multiple testing showing significant
differences between groups, indicated with * p < 0.05 and ** p < 0.01 (dashed lines). The comparison
of COPD + bronchiectasis with the other groups using Mann–Withney U-test showed significant
differences between groups, indicated with † p < 0.05 (solid lines). ODI: optical density index, COPD:
chronic obstructive pulmonary disease, CF: cystic fibrosis.
2.5. Sputum A. fumigatus PCR
When automated DNA extraction was used for A. fumigatus real-time PCR, only three samples
of COPD patients were found to be positive. All of them had high sputum galactomannan levels.
All healthy control samples had a negative PCR result, whereas seven out of twelve CF samples with
known A. fumigatus colonization had a positive PCR result. Five positive control sputum samples
were used to compare automated DNA extraction by EasyMAG and manual extraction by MycXtra®.
All samples had a positive A. fumigatus PCR result after manual DNA extraction compared to only two
positive samples after the automated extraction protocol (Table 4). The comparison between sputum
galactomannan and A. fumigatus PCR is shown in Supplementary Materials Table S2.
Table 4. Comparison of DNA extraction methods in five samples of cystic fibrosis patients with known
A. fumigatus colonization.
Subject Sputum Galactomannan, ODI PCR after EasyMAG Extraction, Ct PCR after MycXtra® Extraction, Ct
CF1 4.4 negative positive, 36.7
CF2 3.7 negative positive, 32.9
CF3 4.7 positive, 29.3 positive, 26.2
CF4 4.6 positive, 30.7 positive, 30.5
CF5 4.7 negative positive, 33.2
Sputum galactomannan is presented as optical density index. PCR is expressed as negative or positive with the
respective Ct value in case of positivity. CF: cystic fibrosis sample, ODI: optical density index, PCR: polymerase
chain reaction, Ct: cycle threshold.
3. Discussion
Sputum alactomannan level suggest a higher load of A. fumigatus in COPD- ronchiectasis-
overlap patients c mpared to COPD patients ithout bronchiectasis. The sputum galactomannan
values were particularly higher in COPD-bronchiectasis-overlap patients that received systemic CS.
Fungal culture has a low sensitivity, even in proven aspergillosis, which contributes to an
underestimation of fungal presence in the airways [18]. In this study, 16.7% of all COPD patients
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showed A. fumigatus in sputum culture. A positive culture was not associated with clinical characteristics
or bronchiectasis. Previous studies reported A. fumigatus positive cultures in 14–37% of COPD
patients [14,19]. In general, culture procedures are not standardized, and the use of different media
and methodologies makes it hard to compare different studies. On the basis of a recent report that
emphasized the use of larger inocula for fungal culture, we compared sputum volumes of 10 µL
and 100 µL [20]. Indeed, we found a higher A. fumigatus culture yield by plating 100 µL of the
samples. Nevertheless, the lack of standardization and low sensitivity urges the need for other
detection methods.
An attractive, alternative method is the detection of galactomannan on sputum samples.
On bronchoalveolar lavage fluid, a galactomannan value of 0.5 is suggestive of the presence of
A. fumigatus, although this cut-off is under debate. Kimura et al. reported 1.2 as the optimal
sputum galactomannan cut-off to diagnose invasive aspergillosis in haematological patients [21],
whereas Baxter et al. used the 0.5 cut-off for Aspergillus positivity in adult CF sputum samples [22].
Recently, the sputum galactomannan results of patients with chronic pulmonary aspergillosis and
allergic bronchopulmonary aspergillosis were found to be much higher, with a cut-off above 6.5
for diagnosis [23]. Our study, which used a comparable homogenization of the samples as the
latter, found ODI values in the same range. Furthermore, we validated these results with negative and
positive controls, which were confirmed by culture and PCR. Despite the higher median galactomannan
ODI in COPD patients with bronchiectasis, our study was not able to define an appropriate cut-off.
The median coefficient of variation to evaluate inter-assay difference was acceptable, although we are
aware that the inter-assay difference was not optimal for some of our samples.
A. fumigatus PCR after automated DNA extraction was less sensitive than culture and
galactomannan detection on COPD sputum samples. Although the performance is good for clear, liquid
samples, our in-house protocol was not suitable for sputum samples, as it does not apply mechanical
forces prior to fungal DNA extraction. Manual DNA extraction with MycXtra, which includes
bead-beating, performed much better in five additionally collected positive control samples. Since this
method required a high sample volume, we were not able to apply this on the other, previously
collected study samples. Furthermore, manual extraction is labor-intensive and not suited for large
laboratories handling many samples on a daily basis. Any protocol for fungal DNA extraction and
PCR on sputum needs further optimization prior to its clinical use.
CS temper the innate immune response, thereby permitting A. fumigatus to persist and proliferate.
In our study, systemic administration of CS was significantly associated with higher sputum
galactomannan values, particularly in patients with COPD–bronchiectasis overlap. These findings
contrast with the study of Huerta et al. in which no association was found between Aspergillus cultures
and oral CS [14]. Differences in the studied population or in the dose of CS administered prior to the
analysis may explain these discrepancies. As the large majority of our study subjects on CS received
high doses in the context of acute exacerbation (40 mg prednisolone), dose–response relationships
could not be studied. Together, our data suggest that systemic CS induce a pronounced and rapid
growth of residing A. fumigatus in the airways, which may predispose to sensitization, bronchiectasis
development, or fungal infection. A local deposition of CS via inhalation may have similar effects.
Bafadhel et al. found that COPD patients with A. fumigatus-positive culture were on higher doses of
inhaled CS compared with culture-negative patients [19]. However, the significance of this association
was weak and could not be confirmed by others [14] nor by our analysis.
Although this study does not allow us to attribute causality, our findings support the hypothesis that
A. fumigatus contributes to the development and/or progression of bronchiectasis in COPD. We recently
showed that the sensitization to specific A. fumigatus allergens was associated with the presence of
bronchiectasis in COPD [5]. Next to an upregulation of the Th2 pathway, Aspergillus proteases may play
an important role through enhanced mucus production and airway remodeling [24,25]. So far, studies
that explored these relationships are solely based on fungal cultures, which may explain some of the
inconclusive results. Sputum galactomannan seems to provide a more sensitive marker for A. fumigatus
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detection in the airways of COPD patients. This advantage may serve new longitudinal observational
studies or even intervention trials in this area.
4. Materials and Methods
4.1. Study Design and Subjects
This academic, single-center study included COPD patients prospectively during hospitalization
or an outpatient visit. The inclusion criteria were an established diagnosis of COPD based on a
post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio < 0.7,
smoking history of at least 10 pack-years, available CT images of the thorax, and an FEV1≥ 30% (safety
measure for sputum induction). The exclusion criteria were ventilation (mechanical and noninvasive),
respiratory diagnosis other than COPD, mycobacterial disease, immunosuppression other than CS,
active cancer treatment, history of lung, tracheal, or laryngeal surgery, history of chest radiotherapy,
and presence of other inflammatory diseases such as rheumatoid arthritis and inflammatory bowel
disease. Investigators were blinded to the results of previous sputum cultures. None of the included
patients had a history of allergic or chronic bronchopulmonary aspergillosis, nor invasive Aspergillus
disease. The presence of bronchiectasis was assessed on CT scans of the lungs. All hospitalized patients
received standard therapy for an exacerbation: CS and antibiotics if indicated. They were included
after sufficient recovery from the acute event. Oral or intravenous CS and antibiotics administered in
the seven days before sputum induction were considered relevant. The study was approved by the
local Ethics Committee (Medical Ethical Board of the University Hospitals Leuven, Belgium—M11223)
and all patients signed informed consent before enrollment.
4.2. Pulmonary Function and Questionnaires
Post-bronchodilator spirometry was measured using standardized equipment (Whole Body
Plethysmograph, Vyaire, Vilvoorde, Belgium), according to the American Thoracic Society/European
Respiratory Society guidelines [26]. Diffusion capacity was measured by the single-breath carbon
monoxide gas transfer method [27]. The results are reported as percentages predicted of reference
values. The post-bronchodilator FEV1 was used to classify the patients according to the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) classification. The patients completed the modified
Medical Research Council (mMRC) breathlessness scale [28], COPD Assessment Test (CAT™) [29],
and Saint Georges Respiratory Questionnaire (SGRQ), a self-administered health-related quality of
life measure.
4.3. CT Thorax
All subjects had a high-resolution CT (HRCT) of the thorax at least one year before enrollment.
All patients had inspiratory images with 1 mm slices. Bronchiectasis were defined based on Naidich’s
descriptions: bronchoarterial ratio > 1, lack of tapering, and presence of bronchus within 1 cm of the
costal pleura or abutting the mediastinal pleura [30]. All images were blinded to the other data and
scored using the modified Reiff score, assessesing the number of involved lobes (the lingula considered
separately) and the degree of bronchodilation (1 = tubular, 2 = varicose, and 3 = cystic) [31].
4.4. Eosinophils, Total IgE, A. fumigatus Sensitization, and A. fumigatus-Specific IgG
Blood samples were collected, and white blood cell count and differentiation were performed by
fluorescence flow cytometry (Sysmex XE-5000, Kobe, Japan). Total IgE, IgE against A. fumigatus extract,
recombinant antigens (rAsp f1-f4 and f6), and A. fumigatus IgG were determined by ImmunoCAP
fluoroenzyme-immunoassay (Phadia AB, Uppsala, Sweden). The skin prick test with crude A. fumigatus
extract (ALK, Almere, The Netherlands) was performed according to the guidelines [32].
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4.5. Sputum Collection, Homogenization, and Culture
In all COPD patients, sputum was induced by inhalation of hypertonic saline (concentration 3%,
4%, and 5% for 5 min each) generated by an Ultra-Neb ultrasonic nebulizer (DeVilbiss, Port Washington,
NY, USA) after pretreatment with 400 µg of inhaled salbutamol. The patient was asked to rinse the
mouth thoroughly with water and spit the sputum into a collection tube [33]. As negative and
positive control samples, induced sputum samples of 7 healthy controls and spontaneous samples
of 12 CF patients with known A. fumigatus colonization were collected, respectively. All samples
were immediately stored at −80 ◦C. For homogenization, an equal volume of Sputasol® (Oxoid,
Thermo Fisher, Hampshire, UK, 1.4% dithiothreitol) was added to each sample. The samples were
subsequently incubated at 37 ◦C for 30 min and shaken every 10 min. Two volumes of each sample,
10 and 100 µL, were inoculated on Sabouraud agar plates (Sabouraud with chloramphenicol (Bio-Rad,
Marnes-la-Coquette, France). The culture plates were incubated at 42 ◦C for 1 day and subsequently at
30 ◦C for 1 week. For each sample, an additional plate without inoculation was incubated as a control.
The growth was checked daily and the colonies were identified by microscopy.
4.6. Sputum Galactomannan Assay
Of the homogenized sputum, 300 µL was transferred to a sterile tube. An enzyme immunoassay
(Platelia™ Aspergillus Ag, Bio-Rad, Marnes-la-Coquette, France) was used to detect galactomannan.
The results are expressed as optical density index (ODI), the ratio of the optical density of the sample to
the mean cut-off control optical density. To exclude false positivity, galactomannan was determined in
Sputasol® and in the sterile water we used to prepare the Sputasol® solution. Furthermore, three vials
from different batches of amoxicillin clavulanate were tested, as some of the hospitalized patients
received this antibiotic, known to influence galactomannan results in previous reports [34]. Moreover,
13 sputum samples were retested to confirm the results.
4.7. Aspergillus PCR on Sputum
A. fumigatus real-time PCR was done following an in-house method with excellent performance
in European Aspergillus PCR Initiative (EAPCRI) evaluations. Nucleic acid extraction was semi-
automatically performed with EasyMAG (Biomérieux, Marcy l’ Etoile, France) using NucliSens
reagents as recommended by the manufacturer. Briefly, 500 µL of sputum samples was lysed in
the presence of magnetic silica beads and subsequently eluted. This method was compared with
a manual extraction method using MycXtra® (Myconostica, Cambridge, UK) in five additionally
collected CF sputum samples with known A. fumigatus colonization. The fungal DNA was extracted
as recommended by the manufacturer. Briefly, 1 mL of the homogenized sample was used for
extraction, then lysis, bead beating, and purification were performed to remove inhibiting substances
with reagents provided by the manufacturer. The nucleic acid extracts where used for real-time
PCR (Quantstudio™, Thermo Fisher Life technologies, Carlsbad, CA, USA). The comparative cycle
threshold was used to normalize data after running through 45 cycles. The used reagents are shown in
the online Supplementary Materials Table S3.
4.8. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 4 (GraphPad Software, La Jolla, CA,
USA) and SAS software version 9.4 (SAS Institute, Cary, NC, USA). Non-parametric tests were used
for analyses. Univariate comparisons were performed by Mann–Withney U-test and presented as
median ± interquartile range. The proportions of discrete variables were compared with χ2 test and
presented as absolute numbers and percentages. The comparison of four groups was performed
with the Kruskal–Wallis and post-hoc Dunn’s tests for multiple comparison. A multivariate model
was built for two-way analysis of variance to study the association between sputum galactomannan,
bronchiectasis, and CS. After performing bivariable models with sputum galactomannan as exposure,
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potential confounders of the association between sputum galactomannan and bronchiectasis were
included in the final model if they (1) changed the estimate of the multivariable model ≥10% or (2)
the variable was significantly associated with galactomannan and bronchiectasis. The interaction
between bronchiectasis and CS was included in the model. p-Values < 0.05 were considered significant
in all analyses.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/2/
523/s1.
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